1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Accelerated Approval Is US FDA Panel’s Preferred Path For Biogen/Ionis’s Tofersen In ALS

 
• By Sue Sutter

Advisory committee unanimously concludes that the reduction in plasma neurofilament light chain concentration is reasonably likely to predict clinical benefit in SOD1-ALS, but majority of panelists say convincing evidence of efficacy to support regular approval has not been demonstrated.

Edge of cliff
Most FDA adcomm members were unwilling to make the leap to regular approval for tofersen. • Source: Shutterstock

The available evidence supports accelerated approval, but not regular approval, for Biogen, Inc. and Ionis Pharmaceuticals, Inc.’s Qalsody (tofersen) in a subgroup of patients with amyotrophic lateral sclerosis, a US Food and Drug Administration advisory committee said on 22 March.

The Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously that a reduction in plasma neurofilament light chain (NfL)...

Welcome to Pink Sheet

Create an account to read this article

Already a subscriber?

More from US FDA Performance Tracker

Single Trial Success Stories: UCB’s Kygevvi Joins US FDA Approvals With Confirmatory Evidence

 
• By Bridget Silverman

The orphan drug share of US FDA’s 2025 novel approvals is holding steady, with examples of approvals based on a single trial with confirmatory evidence from UCB, Precigen, Jazz Pharmaceuticals and Stealth Biotherapeutics

Do US FDA Complete Response Letters Suggest Turn To Less Flexibility In Rare Disease?

 
• By Bridget Silverman

A cluster of CRLs for rare disease applications based on one trial plus confirmatory evidence may represent a shift away from the regulatory flexibility that had come to characterize ultra-rare drug development

Novel US FDA Approvals Could Heat Up November, But Will Annual Count Beat 2024?

 
• By Bridget Silverman

Eight novel agents have user fee goal dates in November, which keeps the possibility of matching or topping the 2024 annual count alive.

Cidara’s Non-Vaccine Flu Preventive Offers Respite From Vaccine Conflicts

 
• By Bridget Silverman

Cidara's CD388 drug-Fc conjugate received a breakthrough designation as the Phase III ANCHOR trial started for once-per-season prevention of influenza in a higher-risk population.

More from Regulatory Trackers

Novel US FDA Approvals Could Heat Up November, But Will Annual Count Beat 2024?

 
• By Bridget Silverman

Eight novel agents have user fee goal dates in November, which keeps the possibility of matching or topping the 2024 annual count alive.

Cidara’s Non-Vaccine Flu Preventive Offers Respite From Vaccine Conflicts

 
• By Bridget Silverman

Cidara's CD388 drug-Fc conjugate received a breakthrough designation as the Phase III ANCHOR trial started for once-per-season prevention of influenza in a higher-risk population.

EU CHMP Opinions And MAA Updates

 
• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.